Want to see PLUR full AI Analyst Report?
Pluri (PLUR) AI Stock Analysis
Pluri
(NASDAQ:PLUR)
Pluri's score of 41 reflects severe financial distress, highlighted by negative equity, substantial losses, and a sharp revenue decline. The recent Nasdaq noncompliance notice adds delisting risk, while technical indicators show a bearish trend and valuation metrics are unattractive. The company faces significant challenges and high risk.
Pluri (PLUR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $13.38M
- Dividend Yield
- ―
- Average Volume (3M)
- 34.27K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 0.84
- Revenue Growth
- -23.95%
- EPS Growth
- 30.12%
- Country
- US
- Employees
- 92
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Pluri Business Overview & Revenue Model
Company Description
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and h...
How the Company Makes Money
Pluri generates revenue through multiple streams, primarily by commercializing its proprietary technologies and cell therapy products. The company licenses its technology to pharmaceutical and biotechnology firms, which pay upfront fees and ongoing r...
Pluri Financial Statement Overview
Summary
Pluri's financial health is very weak: revenue declined 74.9% TTM, net losses of $22.8M, negative equity, debt exceeds assets, and cash flow negative. Some improvement in cash burn but overall distress.
Income Statement
15Very NegativeBalance Sheet
5Very NegativeCash Flow
20Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.02M | 1.02M | 1.34M | 326.00K | 287.00K | 234.00K |
| Gross Profit | 453.00K | 453.00K | 654.00K | 322.00K | 278.00K | -819.00K |
| EBITDA | -24.00M | -24.43M | -22.07M | -20.23M | -27.68M | -39.43M |
| Net Income | -24.45M | -23.82M | -22.58M | -20.89M | -28.32M | -41.24M |
Balance Sheet | ||||||
| Total Assets | 24.88M | 24.88M | 38.68M | 39.53M | 50.80M | 68.06M |
| Cash, Cash Equivalents and Short-Term Investments | 7.80M | 7.80M | 20.61M | 30.24M | 40.17M | 55.02M |
| Total Debt | 34.91M | 34.91M | 34.05M | 29.61M | 29.91M | 28.80M |
| Total Liabilities | 42.31M | 42.31M | 39.55M | 34.11M | 35.50M | 35.88M |
| Stockholders Equity | -23.04M | -23.04M | -6.84M | 96.00K | 13.36M | 30.04M |
Cash Flow | ||||||
| Free Cash Flow | -20.22M | -20.22M | -19.83M | -18.34M | -23.12M | -36.78M |
| Operating Cash Flow | -19.59M | -19.59M | -18.21M | -18.02M | -22.86M | -36.50M |
| Investing Cash Flow | 9.90M | 9.90M | 8.03M | 10.58M | 9.70M | 11.78M |
| Financing Cash Flow | 7.04M | 7.04M | 9.53M | 8.84M | 8.02M | 7.50M |
Pluri Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Positive. The current price of 1.24 is above the 20-day moving average (MA) of 1.03, above the 50-day MA of 1.16, and below the 200-day MA of 2.38, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 61.66 is Neutral, neither overbought nor oversold. The STOCH value of 63.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLUR.
Pluri Risk Analysis
Pluri disclosed 45 risk factors in its most recent earnings report. Pluri reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksPluri Peers Comparison
Overall Rating
PYPD56Neutral
ANTX44Neutral
IGC42Neutral- PLUR41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PYPD | 56Neutral | $109.48M | -3.64 | -311.07% | ― | ― | 61.30% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ANTX | 44Neutral | $170.95M | -4.23 | -53.52% | ― | ― | 13.97% |
| IGC | 42Neutral | $21.49M | -2.25 | -113.58% | ― | ― | ― |
| PLUR | 41Neutral | $15.64M | -0.51 | 144.63% | ― | -23.95% | 30.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PLUR | Pluri Inc. | 1.24 | -2.45 | -66.40% | |
| IGC | Igc Pharma, Inc. | 0.18 | -0.22 | -53.98% | |
| PYPD | PolyPid Ltd. | 5.39 | 1.60 | 42.22% | |
| ANTX | AN2 Therapeutics, Inc. | 4.53 | 3.38 | 293.91% |
Pluri Corporate Events
Pluri in ongoing talks to extend EIB financing
NegativePluri Inc. previously secured a finance agreement with the European Investment Bank for up to €50 million, of which a €20 million tranche bearing 4% annual interest was disbursed in June 2021 and scheduled for repayment on June 1, 2026. A...
Pluri Receives Nasdaq Non-Compliance Notice, Faces Delisting Risk
NegativeOn July 7, 2026, Pluri Inc. disclosed that it had received a notice from Nasdaq stating the company was no longer in compliance with the exchange’s requirement to maintain at least $35 million in market value of listed securities, nor with alte...
Pluri Secures Insider Advance Subscription to Boost Liquidity
PositiveOn June 14, 2026, Pluri Inc. entered into an Advance Subscription Agreement with Chutzpah Holdings LP, an investment vehicle beneficially owned by chairman and existing shareholder Alexandre Weinstein, under which the investor advanced $1.25 million...
Pluri in Good-Faith Talks on EIB Loan Resolution
NegativePluri Inc. previously entered into a finance agreement with the European Investment Bank for up to €50 million, of which a €20 million tranche was disbursed in June 2021 at 4% annual interest and scheduled for repayment on June 1, 2026. O...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 22, 2026